A Phase 1 multi-center clinical trial of AT03-65 in the United States
Latest Information Update: 28 Jan 2025
Price :
$35 *
At a glance
- Drugs AT03 65 (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- Sponsors Axcynsis Therapeutics
- 28 Jan 2025 New trial record
- 15 Jan 2025 According to an Axcynsis Therapeutics media release, company plans to initiate a phase I trial for Solid tumours (Metastatic disease, Late-stage disease, Second-line therapy or greater) in the US in the first quarter of 2025.